Tissue plasminogen activator (t-PA) and urokinase (u-PA), the major activators of plasminogen, are synthesized and released from endothelial cells. We previously demonstrated specific and functional binding of plasminogen to cultured human umbilical vein endothelial cells (HUVEC). In the present study we found that t-PA could bind to HUVEC. Binding of t-PA to HUVEC was specific, saturable, plasminogen-independent, and did not require lysine binding sites. 
Introduction
Human tissue plasminogen activator (t-PA)' is a single chain seine protease of M, 68,000. This enzyme is synthesized and secreted by endothelial cells and is one of the two major circulating plasminogen activators (1) . After cleavage with plasmin (2, 3) , two distinct portions of the molecule have been defined, light chain (M, 32 ,000) which contains the active site (4, 5) .
The light chain of t-PA shows considerable homology with other serine proteases (6, 7) . For optimal activity, t-PA requires fibrin as a cofactor that augments its catalytic efficiency by two to three orders of magnitude, possibly via formation of a cyclic ternary complex involving t-PA, plasminogen, and fibrin (8) . Other proteins such as thrombospondin and histidine-rich glycoprotein may also enhance the enzymatic activity of t-PA in vitro (9) .
In addition to t-PA, cultured endothelial cells synthesize and secrete urokinase-like plasminogen activators (u-PA) (10) (11) (12) , and a plasminogen activator inhibitor (PAI) (10, 13) . In the resting state, both forms of plasminogen activator are measurable in plasma (50-100 pM and -100 pM, respectively), and additional t-PA is released from the vascular wall after various stimuli (14) . Cultured bovine capillary endothelial cells secrete t-PA into the medium, and binding to the surface is minimal (15) . However, it is not clear whether large vessel endothelial cells behave similarly. In contrast, u-PA binds to human monocytes and a monocytic cell line (U937) (16, 17) , normal and virus-transformed fibroblasts (3T3) (18, 19) , a human epidermoid carcinoma (A43 1) cell line (20) (21) (22) , and possibly bovine corneal (23) and capillary (15) endothelial cells.
We recently reported binding and activation of human glu-plasminogen on the surface of cultured human umbilical vein endothelial cells (HUVEC) (24) . Binding was specific, of high affinity, and associated with a log-order increase in catalytic activity when bound zymogen was activated by t-PA. We now demonstrate plasminogen-independent, specific, and saturable binding of t-PA to both high-and low-affinity sites on the HUVEC surface. Binding was independent of the lysinebinding sites of t-PA, and was 70% inhibitable by a 100-fold molar excess of urokinase. t-PA binding to HUVEC was associated with preservation of enzyme activity as determined by plasminogen activation, and binding protected t-PA from its fast-acting inhibitor, PAL.
Methods
Materials. 96 (Falcon Labware, Oxnard, CA) and 24 (Costar, Cambridge, MA)-well tissue culture plates were employed. L-Glutamine, penicillin-streptomycin, fungizone, porcine intestinal mucosal heparin, BSA (essentially fatty acid-and globulin-free), lactoperoxidase, tissue culture grade EDTA, p-nitrophenylphosphate, I-arginine, and l-lysine were from Sigma Chemical Co., St. Louis, MO ELISAs with antibodies to human albumin, aI-antitrypsin, a2-plasmin inhibitor, a2-macroglobulin, or histidine-rich glycoprotein. The cell surface was specifically unreactive toward fibrinogen at an antibody dilution of 1:500. At this level, the antibody could detect human fibrinogen applied to polystyrene wells in coating concentrations as low as 0. 147 fmol/well. Cell monolayers reacted strongly with rabbit antiserum to human lung angiotensin converting enzyme, rabbit antiserum to whole HUVEC, and with rabbit IgG directed against human fibronectin, each at dilutions of up to 1:50,000.
Cell quantitation. Each well to be counted was washed once with Hepes-buffered saline. Cells were detached by incubation (20 min, 37°C) with Hepes-buffered saline containing 0.05% type I collagenase, 0.01% EDTA, and 0.25% BSA. After gentle trituration, the single-cell suspensions were enumerated in a hemocytometer. Counts were verified in an electronic apparatus (Model ZBI, Coulter Electronics Inc., Hialeah, FL). Trypan blue exclusion by the cells was 98%.
Cell monolayer ELISAs. Cell monolayer ELISAs were carried out essentially as previously described (24) . For t-PA binding studies, monolayers were equilibrated to 4°C (5 min), washed once with incubation buffer (IB [2] ), once with IB(2) containing 10 mM EACA, and three times again with IB(2). Various concentrations of t-PA or other control proteins (100 ,l/well) were then added and the plates incubated at 4°C for various time periods. The monolayers were then washed three times with cold IB(2), lightly fixed with 0.02% glutaraldehyde, washed again three times, and exposed to rabbit anti-human t-PA (3 h, 37°C). After three additional washes, the cells were exposed to alkaline phosphatase-conjugated goat anti-rabbit IgG (3 h, 37°C or 18 h, 4°C). After three final washes, the alkaline phosphatase substrate p-nitrophenylphosphate was added and substrate hydrolysis monitored at 405 nm as a reflection of protein binding.
Radioisotope labeling. Human recombinant t-PA was radio-iodinated by the lactoperoxidase method (26) . Labeling was carried out for 3 min at 20°C in a total volume of 390 gl at pH 7.4 using a reaction mixture consisting of 4 As demonstrated in Fig. 2 , HUVEC bound t-PA rapidly, reaching a steady state at -10 min. Reversibility of binding was shown by "infinite dilution" of unbound ligand at 10 min. At this time point, the t-PA dissociation curve was biphasic with a rapid initial dissociation phase during the first 2.5 min (T1/2, 9 min) followed by a slower second phase over the next 24 min (T1/2, 54 min). Under conditions utilized, 77% of total binding was dissociable.
Binding of t-PA by HUVEC was relatively specific for this cell type (Fig. 3) . Control cells such as those from bovine endoProtein, nM Figure 1 . Interaction of t-PA, u-PA, and prothrombin with HUVEC. HUVEC were grown to confluency in plasminogen-depleted medium, equilibrated to 4°C, and washed in IB and IB/EACA as described in Methods. HUVEC were then incubated for 30 min with various concentrations (0.4-28.4 nM) of recombinant t-PA (-), u-PA (a), or prothrombin (A). The monolayers were washed three times and lightly fixed with 0.02% glutaraldehyde. After three additional washes with PBS/Tween/BSA, rabbit anti-human t-PA, u-PA, or prothrombin at dilutions of 1:1,000 in PBS/Tween were added and incubated at 37°C for 3 h. The monolayers were then washed again and exposed for 18 h at 4°C to alkaline phosphatase-conjugated goat anti-rabbit IgG diluted to 1:1,000 in PBS/Tween. After three additional washes, protein binding was measured as a reflection of change in absorbance over time. Each point represents the average of duplicate samples. with 300 ul IB starting at 10 min to effect 'infinite dilution' as previously described (24) . These wells were subsequently washed three times and fixed at the indicated time points. Bound t-PA was assayed in each well as described in Fig. 1 Inhibition of binding of '251I-t-PA by increasing molar excesses of unlabeled t-PA was quantified in a "cold competition assay" (Fig. 4) . A fivefold molar excess of unlabeled t-PA induced 50% inhibition of 1251I-t-PA binding which indicated that the two ligands were nearly equal in competition for binding sites on HUVEC. A 100-125-fold molar excess of unlabeled t-PA-induced 85% inhibition of '251-t-PA binding. In two experiments where it was tested, a 1,000-fold excess of cold t-PA blocked 95% of '251I-t-PA binding to HUVEC. Based on these results, we conclude that nonspecific binding represents < 15% of total binding.
Lysine binding sites are important functional determinants in the t-PA molecule and are implicated in the binding oft-PA to fibrinogen. Therefore, binding oft-PA by HUVEC was evaluated in the presence of lysine analogs (Table I) . Omegaaminocarboxylic acids did inhibit binding of t-PA by HUVEC by 70-80%, but relatively high concentrations of these acids were required to achieve such inhibition (150, 38-54 mM; l05-106 fold molar excess). Binding could also be inhibited by 70-80% with the use of a chaotropic agent (NH4SCN, I50 = 65 mM) or by increasing the ionic strength of the medium (NaCl, 150 = 135 mM). In addition, binding oft-PA by HUVEC could not be inhibited by a 100-fold molar excess of fluid phase fibrinogen (Fig. 5) . It was therefore concluded that lysine binding sites of t-PA per se did not play a major role in the binding interaction between HUVEC and t-PA.
Inhibition oft-PA binding by u-PA. The ability of HUVEC to bind t-PA in the presence of excess quantities of several control proteins including u-PA was studied (Fig. 5) . Murine epidermal growth factor, human fibrinogen, prothrombin, plasminogen, plasminogen "kringle" 1,2,3, and fibronectin did not induce significant inhibition of t-PA binding. However, HUVEC binding of t-PA was blocked by urokinase in a concentration-dependent manner. At a 14.5±4.0 (SE, n = 6)-fold molar excess of u-PA, 50% inhibition of binding was observed. A 50-100-fold excess of u-PA blocked binding by -70%. As demonstrated by SDS-PAGE autoradiography, inhibition of binding by u-PA was not due to proteolytic cleavage of t-PA (data not shown). These results indicate that t-PA and u-PA probably share a common binding site on the HUVEC surface.
Binding interaction between HUVEC and '25I-t-PA. To precisely quantify the binding affinity and capacity of HUVEC HUVEC in 24-well tissue culture dishes were prepared as described in Fig. 1 Functional properties of bound t-PA. Experiments were carried out to determine whether the t-PA bound by HUVEC still retained its capacity for plasminogen activation. We found that fluid phase activation of plasminogen by t-PA followed Michaelis-Menten kinetics, as reported by other investigators (8, 32) . When t-PA was bound to HUVEC, plasminogen activation by the bound material also conformed to MichaelisMenten kinetics as demonstrated by linear Lineweaver-Burk plots. The catalytic efficiency of bound t-PA was compared with that of an equivalent quantity of fluid phase t-PA with the use of a fluorometric assay for t-PA activity. In three separate experiments it could be demonstrated that binding of t-PA to HUVEC resulted in an average 2.6-fold decrease in the cata- lytic rate constant (kcA), accompanied by an eightfold decrease in apparent Km (Table TI) . This was reflected by a significant (average 3.2-fold) increase in catalytic efficiency (kcadKm). Direct linear plot was used to verify calculated values for Vma.
and Km (Enzpack program, Elsevier-Biosoft; Cambridge, UK). HUVEC alone produced negligible amounts of fluid phase plasminogen activation over a period of several hours. Therefore, the effect observed was not due to elaboration of plasminogen activators in the fluid phase. It was concluded that cell-bound t-PA retained full functional capacity and was at least as strong a catalytic agent as t-PA in the fluid phase. t-PA in the fluid phase is known to be susceptible to rapid inhibition by plasminogen activator inhibitor (PAI). We tested the inhibitory effect of PAI-enriched postculture medium on t-PA which was bound to HUVEC (Table III) . At molar ratios of up to 20:1 (PAI:t-PA), bound t-PA was insensitive to this t-PA inhibitory activity was measured in a fluorogenic assay system consisting of plasminogen (154 nM), AFC plasmin substrate (167 MM), fluid phase (0.214 nM) or cell surface-bound t-PA, and various molar ratios of PAL. t-PA activity was measured in relative fluorescence units as previously described (24) for wells containing or lacking HUVEC, and the molar ratio (PAI:t-PA) that produced 50% inhibition of substrate hydrolysis was calculated. Values shown are mean±SE (n = 4).
inhibitor, whereas fluid phase t-PA was inhibited by 50% at an estimated molar ratio of 0.5:1. This inhibitory factor in postculture medium was 85-90% adsorbed by antibody to human PAI-I at a dilution of 1:50, but not by similar concentrations of a control antibody (mouse anti-human F, receptor), in the presence of protein A-Sepharose. In addition, preincubation of PAI-enriched post-culture medium with confluent monolayers of HUVEC (220C, 150 min) did not significantly reduce its t-PA-inhibitory activity, suggesting that PAI was not adsorbed by the cells and also that the cells did not produce a product that competes with or inactivates PAL. Thus, the data indicate that following binding of t-PA by HUVEC, the active site ofthe enzyme becomes relatively inaccessible to this physiologic inhibitor, suggesting that its fibrinolytic potential would be enhanced.
Discussion
Results of the present study constitute the first demonstration of specific tissue plasminogen activator binding to monolayers of human umbilical vein endothelial cells. The interaction of t-PA with HUVEC was protein-specific, although other "kringle"-containing proteins such as plasminogen and plasmin also bound to the HUVEC surface (24) . However, a nonfibrinolytic "kringle"-containing protein, prothrombin (33) , was not bound at all by HUVEC. The binding reaction was species-specific, because t-PA bound with varying affinity to three human cell types (endothelial cells, fibroblasts, and smooth muscle cells), but not to two bovine cell lines (endothelium and smooth muscle) (Fig. 3) . (Fig. 5) .
The interaction oft-PA with cultured HUVEC is a two-site binding system. This was evidenced by the radioligand binding data which clearly indicated two discrete saturable binding sites (P < 0.0001). The shape of the binding isotherms also suggested a two-site system, wherein a rapid increase in binding at low t-PA input concentrations was followed by a more gradual increase in binding as higher concentrations were approached (Fig. 1, 3 , and 6). Furthermore, the shape of the binding dissociation curve also suggested a two-phase process with different rates of dissociation (Fig. 2) . Even though the radioligand binding studies were not carried out under strict equilibrium conditions, reasonable estimates of binding affinity and capacity were provided via excellent agreement with those obtained by ELISA. Finally, the cold competition assay system validated the '25I-t-PA data by providing verification that labeled and unlabeled ligand competed for the cell surface with approximately equal affinity (Fig. 4) . Under baseline conditions, the level of t-PA in human plasma is 50-100 pM (14, 34, 35) ; following physical exercise, vaso-occlusion, or infusion of l-deamino-8-D-arginine vasopressin (DDAVP), plasma levels oft-PA increase threefold (34, 35 The precise mechanism whereby HUVEC bound t-PA to their surface remains to be elucidated. Although the fibrinbinding domain oft-PA involves the "kringle"-2 segment (and to a lesser extent the fibronectin "finger" and epidermal growth factor regions [36, 37] ), it is unlikely that the fibrin binding domain of t-PA is germane to the interactions we studied. This is evidenced by our demonstration that the HUVEC employed in these experiments contained insufficient surface fibrinogen to account for the degree of binding attained. Furthermore, binding of t-PA to the HUVEC surface was not blocked by fluid phase fibrinogen (Fig. 5) . In addition, relatively high (mM) concentrations of lysine analogs are required to induce significant inhibition oft-PA binding, and the inhibition that did occur may have been a reflection of an increase in ionic strength of the medium (Table I) . Whereas plasminogen does exhibit a lysine binding site-dependent interaction with the HUVEC surface (24) , neither plasminogen nor its elastase-derived fragment, "kringle 1,2,3", blocked binding of t-PA by HUVEC, even when present in 100-fold molar excess (Fig. 5) .
Although urokinase strongly inhibits t-PA binding to HUVEC, other proteins which are structurally homologous (epidermal growth factor, plasminogen, plasminogen-derived "kringle" 1,2,3, fibronectin, fibrinogen, and prothrombin) did not do so (Fig. 5) . Both urokinase and t-PA both possess growth factor, "kringle," and catalytic domains which demonstrate varying degrees of homology (6, 7) . The amino terminal fragment of u-PA which contains the growth factor and "kringle" domains appears to mediate u-PA binding to human monocytic and epidermoid carcinoma cell lines (38). As depicted in Fig. 5 , one of these two or possibly an as yet undefined domain may be responsible for the binding function of t-PA by HUVEC.
It is important to note that t-PA retains its activity as a catalytic agent after it has been bound by HUVEC (Table II) .
This did not represent release of a soluble endothelial cell component(s) because endothelial cell postculture medium was incapable of activating plasminogen in the time frame of this assay. Upon binding of t-PA by HUVEC, we measured a 3.2-fold increase in its catalytic efficiency (Table II) . Upon binding of t-PA to fibrin, the same reaction proceeds -500 times more efficiently (8) , suggesting that the endothelial cell may have a fibrinlike effect, albeit of much lower magnitude. The basis of the HUVEC-induced increase in catalytic efficiency, like that conferred by fibrin, was a decrease (eightfold) in the apparent Km. We have previously demonstrated (24) that plasminogen also binds to HUVEC, and that binding augments its activatability by 12-fold, based on a proportionate decrease in apparent Km. The concentrations of plasminogen used in the t-PA activation experiments were at or below the Kd for the interaction of plasminogen with HUVEC. Thus, under these assay conditions, plasminogen binding sites could be partially occupied, and the eightfold decrease in Km observed for plasminogen activation by cell surface t-PA may reflect, at least in part, a contribution from plasminogen bound to the cell surface.
The endothelial cell surface appears to confer protection of t-PA with respect to its physiologic inhibitor, PAL. Although the mechanism for this protection is unclear, this phenomenon has been reported in other enzyme systems. Thus, plasmin bound to a fibrin surface is sequestered from the action of circulating antiplasmin (39) , and acrosin from ram seminal vesicle is protected from its inhibitor in seminal plasma (40) . In cellular systems, urokinase which becomes macrophage-associated is not susceptible to the action of PAI, whereas plasminogen activator in the fluid phase is exquisitely sensitive to PAI (41, 42) . Therefore, active site protection, whereby proteases acquire increased catalytic activity upon association with physiologically relevant surfaces, may represent a broad physiologic mechanism. This protection is ofpertinence in our system, because the phenomenon augments fibrinolytic potential in a plasma milieu where a thrombus might be located in the in vivo situation.
In previous studies (24), we demonstrated that plasminogen, the major substrate for t-PA, bound in a specific manner and with high affinity to cultured HUVEC in physiologic concentrations. Data presented in the experiments described have indicated that t-PA was also bound in vitro under comparable circumstances. Similar data concerning binding of plasminogen and urokinase to the promyeloid leukemic cell line (U937) and a fetal lung fibroblast cell line (GM 1380) have been recently reported by Plow et al. (43) . The binding described in the present study may be physiologically relevant in the course of events such as venous occlusion or physical stress. Although the t-PA binding site was not identical to the plasminogen binding site or plasminogen itself, the reaction allowed t-PA to retain its ability to activate plasminogen and the bound t-PA was inaccessible to its rapidly-acting inhibitor, PAL. Therefore, the endothelial cell, by virtue of its ability to provide specific binding sites for the assembly of proteins of the fibrinolytic system, may serve as a focal point for plasmin generation in the blood vessel microenvironment.
